🇪🇺 CATUMAXOMAB in European Union

EMA authorised CATUMAXOMAB on 10 February 2025

Marketing authorisation

EMA — authorised 10 February 2025

Application: EMEA/H/C/005697
Marketing authorisation holder: Atnahs Pharma Netherlands B.V.
Local brand name: Korjuny
Indication: Korjuny is indicated for the intraperitoneal treatment of malignant ascites in adults with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas, who are not eligible for further systemic anticancer therapy.
Status: approved

The European Medicines Agency (EMA) approved Korjuny (CATUMAXOMAB) on 10 February 2025. Korjuny is a treatment for malignant ascites in adults with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas. This condition is a build-up of fluid in the abdomen due to cancer. Patients who are not eligible for further systemic anticancer therapy can receive Korjuny intraperitoneally.

Read official source →

CATUMAXOMAB in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is CATUMAXOMAB approved in European Union?

Yes. EMA authorised it on 10 February 2025.

Who is the marketing authorisation holder for CATUMAXOMAB in European Union?

Atnahs Pharma Netherlands B.V. holds the EU marketing authorisation.